<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204646</url>
  </required_header>
  <id_info>
    <org_study_id>jth_005</org_study_id>
    <nct_id>NCT00204646</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)</brief_title>
  <official_title>Phase II Study of Neoadjuvant Dose-Intensive Chemotherapy With Adriamycin and Ifosfamide Followed by High-Dose ICE in Locally Advanced Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      Complete resection is still the only curative treatment option in patients with soft tissue&#xD;
      sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without&#xD;
      evidence of metastatic disease. The aim of this trial is to determine whether neoadjuvant&#xD;
      dose-intensive chemo-radiotherapy is a feasible and effective approach in patients with&#xD;
      non-resectable STS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Sarcoma, Soft Tissue</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed STS with locally advanced non-resectable disease&#xD;
&#xD;
          -  Metastatic disease is allowed in case of solitary resectable metastases&#xD;
&#xD;
          -  Grading according to Coindre &gt; IIÂ°&#xD;
&#xD;
          -  Measurable tumor lesions&#xD;
&#xD;
          -  Age &gt; 18 through 65 years&#xD;
&#xD;
          -  Karnofsky status &gt; 70 %&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy&#xD;
&#xD;
          -  Intercurrent disease interfering with the adequate administration of study medication&#xD;
             including severe psychological disease&#xD;
&#xD;
          -  Insufficient liver-, renal or bone marrow function&#xD;
&#xD;
          -  Evidence of pregnancy&#xD;
&#xD;
          -  Treatment within another clinical trial&#xD;
&#xD;
          -  Uncontrolled viral Infections (HIV,HBV, HCV)&#xD;
&#xD;
          -  other malignancies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg T. Hartmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South West German Cancer Center, Medical Center II, University of Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center II, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 19, 2007</last_update_submitted>
  <last_update_submitted_qc>April 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

